Skip to Main Content

Author Details

Christopher P Evans
University of California Davis
1988
234
59
PMIDPaper TitleJournal TitlePublished Year
37423774The Impact of Positron Emission Tomography Imaging and Tumor Molecular Profiling on Risk Stratification, Treatment Choice, and Oncological Outcomes of Patients with Primary or Relapsed Prostate Cancer: An International Collaborative Review of the Existing Literature.Eur Urol Oncol2024
36596844Novel inhibition of AKR1C3 and androgen receptor axis by PTUPB synergizes enzalutamide treatment in advanced prostate cancer.Oncogene2023
37969642Cardiovascular Effects of GnRH Antagonists Compared With Agonists in Prostate Cancer: A Systematic Review.JACC CardioOncol2023
37289025The Genomic and Epigenomic Landscape of Double-Negative Metastatic Prostate Cancer.Cancer Res2023
37284045The Metastatic Risk of Renal Cell Carcinoma by Primary Tumor Size and Subtype.Eur Urol Open Sci2023
37147019Androgen receptor blockade resistance with enzalutamide in prostate cancer results in immunosuppressive alterations in the tumor immune microenvironment.J Immunother Cancer2023
37003085Management of patients with advanced prostate cancer-metastatic and/or castration-resistant prostate cancer: Report of the Advanced Prostate Cancer Consensus Conference (APCCC) 2022.Eur J Cancer2023
36773708Allosteric inhibition of HSP70 in collaboration with STUB1 augments enzalutamide efficacy in antiandrogen resistant prostate tumor and patient-derived models.Pharmacol Res2023
36494221Management of Patients with Advanced Prostate Cancer. Part I: Intermediate-/High-risk and Locally Advanced Disease, Biochemical Relapse, and Side Effects of Hormonal Treatment: Report of the Advanced Prostate Cancer Consensus Conference 2022.Eur Urol2023
34993496Genetic Factors Associated with Prostate Cancer Conversion from Active Surveillance to Treatment.HGG Adv2022
35440417Corrigendum to "What Experts Think About Prostate Cancer Management During the COVID-19 Pandemic: Report from the Advanced Prostate Cancer Consensus Conference 2021" [Eur Urol 82(1):6-11].Eur Urol2022
35450732Management of Patients with Advanced Prostate Cancer: Report from the Advanced Prostate Cancer Consensus Conference 2021.Eur Urol2022
36109521Transcriptional profiling of matched patient biopsies clarifies molecular determinants of enzalutamide-induced lineage plasticity.Nat Commun2022
35930737Bioengineered BERA-Wnt5a siRNA Targeting Wnt5a/FZD2 Signaling Suppresses Advanced Prostate Cancer Tumor Growth and Enhances Enzalutamide Treatment.Mol Cancer Ther2022
35892678The Immunotherapy and Immunosuppressive Signaling in Therapy-Resistant Prostate Cancer.Biomedicines2022
36159187Activation of neural lineage networks and ARHGEF2 in enzalutamide-resistant and neuroendocrine prostate cancer and association with patient outcomes.Commun Med (Lond)2022
36251389The 5-Hydroxymethylcytosine Landscape of Prostate Cancer.Cancer Res2022
33608234How Should Molecular Markers and Magnetic Resonance Imaging Be Used in the Early Detection of Prostate Cancer?Eur Urol Oncol2022
35086956Olaparib-Induced Senescence Is Bypassed through G2-M Checkpoint Override in Olaparib-Resistant Prostate Cancer.Mol Cancer Ther2022
33048621Newly Diagnosed High-Risk Prostate Cancer in an Era of Rapidly Evolving New Imaging: How Do We Treat?J Clin Oncol2021
33737681Phase Ib trial of reformulated niclosamide with abiraterone/prednisone in men with castration-resistant prostate cancer.Sci Rep2021
33785255Recent Advances in Epigenetic Biomarkers and Epigenetic Targeting in Prostate Cancer.Eur Urol2021
33916325Targeting Feedforward Loops Formed by Nuclear Receptor RORγ and Kinase PBK in mCRPC with Hyperactive AR Signaling.Cancers (Basel)2021
33745687Impact of Pelvic Lymph Node Dissection and Its Extent on Perioperative Morbidity in Patients Undergoing Radical Prostatectomy for Prostate Cancer: A Comprehensive Systematic Review and Meta-analysis.Eur Urol Oncol2021
34554200Prognosis Associated With Luminal and Basal Subtypes of Metastatic Prostate Cancer.JAMA Oncol2021
34459214Cardiovascular Safety of Degarelix Versus Leuprolide in Patients With Prostate Cancer: The Primary Results of the PRONOUNCE Randomized Trial.Circulation2021
34129025Comparison of Joint and Landmark Modeling for Predicting Cancer Progression in Men With Castration-Resistant Prostate Cancer: A Secondary Post Hoc Analysis of the PREVAIL Randomized Clinical Trial.JAMA Netw Open2021
34326198Activation of the <i>ABCB1</i> Amplicon in Docetaxel- and Cabazitaxel-Resistant Prostate Cancer Cells.Mol Cancer Ther2021
34272475ARVib suppresses growth of advanced prostate cancer via inhibition of androgen receptor signaling.Oncogene2021
34119382Re: Regional Adoption of Commercial Gene Expression Testing for Prostate Cancer.Eur Urol2021
31532258Utility of Intraprocedural Contrast-Enhanced CT in Ablation of Renal Masses.AJR Am J Roentgenol2020
34396210Cardiovascular Safety of Degarelix Versus Leuprolide for Advanced Prostate Cancer: The PRONOUNCE Trial Study Design.JACC CardioOncol2020
32001144Management of Patients with Advanced Prostate Cancer: Report of the Advanced Prostate Cancer Consensus Conference 2019.Eur Urol2020
31745256Germline polymorphisms associated with impaired survival outcomes and somatic tumor alterations in advanced prostate cancer.Prostate Cancer Prostatic Dis2020
31951493Framing Pragmatic Strategies to Reduce Mortality From Bladder Cancer: An Endorsement From the Society of Urologic Oncology.J Clin Oncol2020
31892469A Case Series of Preoperative Endovascular Stenting in Patients Undergoing Postchemotherapy Resection of Complex Oncologic Masses.Eur Urol Oncol2020
31712394Therapeutic Targeting of MDR1 Expression by RORγ Antagonists Resensitizes Cross-Resistant CRPC to Taxane via Coordinated Induction of Cell Death Programs.Mol Cancer Ther2020
32852528Assessment of Postprostatectomy Radiotherapy as Adjuvant or Salvage Therapy in Patients With Prostate Cancer: A Systematic Review.JAMA Oncol2020
32706639Cancer and Leukemia Group B 90203 (Alliance): Radical Prostatectomy With or Without Neoadjuvant Chemohormonal Therapy in Localized, High-Risk Prostate Cancer.J Clin Oncol2020
32928794Steroid Sulfatase Stimulates Intracrine Androgen Synthesis and is a Therapeutic Target for Advanced Prostate Cancer.Clin Cancer Res2020
32727885Copy Number Loss of 17q22 Is Associated with Enzalutamide Resistance and Poor Prognosis in Metastatic Castration-Resistant Prostate Cancer.Clin Cancer Res2020
32430485Cross-Resistance Among Next-Generation Antiandrogen Drugs Through the AKR1C3/AR-V7 Axis in Advanced Prostate Cancer.Mol Cancer Ther2020
32424106Transcriptional profiling identifies an androgen receptor activity-low, stemness program associated with enzalutamide resistance.Proc Natl Acad Sci U S A2020
30466892Re: Radiotherapy to the Primary Tumour for Newly Diagnosed, Metastatic Prostate Cancer (STAMPEDE): A Randomised Controlled Phase 3 Trial.Eur Urol2019
30072740KDM8/JMJD5 as a dual coactivator of AR and PKM2 integrates AR/EZH2 network and tumor metabolism in CRPC.Oncogene2019
30115959Non-metastatic castration resistant prostate cancer: a review of current and emerging medical therapies.Prostate Cancer Prostatic Dis2019
31511827Wntless promotes cellular viability and resistance to enzalutamide in castration-resistant prostate cancer cells.Am J Clin Exp Urol2019
31341032GnRH Antagonists Have Direct Inhibitory Effects On Castration-Resistant Prostate Cancer Via Intracrine Androgen and AR-V7 Expression.Mol Cancer Ther2019
31308078AKR1C3 Promotes AR-V7 Protein Stabilization and Confers Resistance to AR-Targeted Therapies in Advanced Prostate Cancer.Mol Cancer Ther2019
31155470Association of an organ transplant-based approach with a dramatic reduction in postoperative complications following radical nephrectomy and tumor thrombectomy in renal cell carcinoma.Eur J Surg Oncol2019
  • 1 - 50 of 234

Recommended Authors

Pedro Isaacsson Velho
Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins
Career Start Year 2013
Number of shared co-authors 16
Izak Faiena
Columbia University Medical Center
Career Start Year 2010
Number of shared co-authors 4
Alastair D Lamb
University of Oxford
Career Start Year 2007
Number of shared co-authors 15
Arun A Azad
Peter MacCallum Cancer Centre
Career Start Year 2007
Number of shared co-authors 24
Jonathan L Wright
University of Washington Medical Center
Career Start Year 2005
Number of shared co-authors 27
Amirali Salmasi
University of California San Diego
Career Start Year 2005
Number of shared co-authors 6
Channing J Paller
Johns Hopkins University School of Medicine
Career Start Year 2004
Number of shared co-authors 27
Anne Y Warren
Cambridge University Hospitals National Health Service Foundation Trust
Career Start Year 2003
Number of shared co-authors 14
Scott T Tagawa
Meyer Cancer Center, Weill Cornell Medicine-NewYork Presbyterian Hospital
Career Start Year 2003
Number of shared co-authors 48
Ashley E Ross
Northwestern University
Career Start Year 2003
Number of shared co-authors 55
Jun Hyuk Hong
Asan Medical Center, University of Ulsan College of Medicine
Career Start Year 2002
Number of shared co-authors 7
Ladan Fazli
University of British Columbia
Career Start Year 2002
Number of shared co-authors 48
Antonio Hurtado-Coll
University of British Columbia
Career Start Year 2002
Number of shared co-authors 36
Mark C Markowski
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Career Start Year 2001
Number of shared co-authors 14
Ganesh V Raj
University of Texas Southwestern Medical Center at Dallas
Career Start Year 1994
Number of shared co-authors 40
Louis Lacombe
CHU de Quebec-Universite Laval
Career Start Year 1994
Number of shared co-authors 17
Raymond S Lance
Washington State University Elson S. Floyd College of Medicine
Career Start Year 1992
Number of shared co-authors 16
Marshall Scott Lucia
University of Colorado School of Medicine
Career Start Year 1991
Number of shared co-authors 8
Bruce Montgomery
Fred Hutchinson Cancer Center, University of Washington
Career Start Year 1990
Number of shared co-authors 52
Anthony V D'Amico
Duke University Medical Center
Career Start Year 1988
Number of shared co-authors 45
Philip Cornford
Liverpool University Hospitals
Career Start Year 1988
Number of shared co-authors 10
Armen Aprikian
McGill University Health Centre, McGill University
Career Start Year 1987
Number of shared co-authors 16
Alan W Partin
The Brady Urological Institute, Johns Hopkins University School of Medicine
Career Start Year 1987
Number of shared co-authors 43
Bruce J Trock
Johns Hopkins University School of Medicine
Career Start Year 1984
Number of shared co-authors 42
Joseph L Chin
University of Western Ontario
Career Start Year 1982
Number of shared co-authors 18
Hendrik Van Poppel
University Hospitals Leuven
Career Start Year 1981
Number of shared co-authors 33
David E Neal
University of Oxford, John Radcliffe Hospital
Career Start Year 1981
Number of shared co-authors 35
Kenneth J Pienta
The Brady Urological Institute, Johns Hopkins University School of Medicine
Career Start Year 1981
Number of shared co-authors 53
Mario A Eisenberger
Johns Hopkins University
Career Start Year 1977
Number of shared co-authors 49
John Trachtenberg
University of Toronto, University Health Network
Career Start Year 1971
Number of shared co-authors 17

Collaborators

Primo N Lara
University of California Davis Comprehensive Cancer Center
Co-authored papers 35
Martin E Gleave
University of British Columbia
Co-authored papers 27
Derya Tilki
Universitatsklinikum Hamburg-Eppendorf
Co-authored papers 26
Tomasz M Beer
OHSU Knight Cancer Institute, Oregon Health & Science University
Co-authored papers 25
Eric J Small
University of California san francisco
Co-authored papers 21
Felix Y Feng
UCSF Medical Center-Mount Zion
Co-authored papers 21
Robert E Reiter
David Geffen School of Medicine at university of california los angeles
Co-authored papers 18
Joshi J Alumkal
Rogel Cancer Center, University of Michigan ann arbor
Co-authored papers 16
Kim N Chi
University of British Columbia
Co-authored papers 15
Rahul Aggarwal
University of California San Francisco
Co-authored papers 15
Matthew B Rettig
David Geffen School of Medicine, University of California los angeles
Co-authored papers 14
Adam Foye
University of California San Francisco
Co-authored papers 14
Celestia S Higano
University of Washington and Fred Hutchinson Cancer Research Center
Co-authored papers 14
Jiaoti Huang
Duke University School of Medicine
Co-authored papers 12
Fred Saad
University of Montreal Health Center
Co-authored papers 11
Cora N Sternberg
Meyer Cancer Center, Englander Institute for Precision Medicine
Co-authored papers 10
David A Quigley
University of California-San Francisco
Co-authored papers 10
Owen N Witte
University of California los angeles
Co-authored papers 9
Himisha Beltran
Dana-Farber Cancer Institute
Co-authored papers 9
Michael J Morris
Memorial Sloan Kettering Cancer Center
Co-authored papers 8
Howard I Scher
Memorial Sloan Kettering Cancer Center
Co-authored papers 8
Mary-Ellen Taplin
Lank Center for Genitourinary Oncology, Dana-Farber Cancer Institute
Co-authored papers 8
Anders Bjartell
Skane University Hospital, Lund University
Co-authored papers 8
Johann S de Bono
The Institute for Cancer Research
Co-authored papers 8
Joshua M Stuart
University of California at Santa Cruz
Co-authored papers 8
Daniel E Spratt
University Hospitals Seidman Cancer Center, Case Western Reserve University
Co-authored papers 7
Declan G Murphy
Peter MacCallum Cancer Centre, University of Melbourne
Co-authored papers 7
Nicolas Mottet
Hospitalier Universitaire de Saint-Etienne
Co-authored papers 7
Maha Hussain
Northwestern University
Co-authored papers 7
Paul Lloyd
Bluestar Genomics Inc.
Co-authored papers 7
Release 1.2